Mr. Speaker, from the outset, we have relied on experts who have given us recommendations on investments we could make here in Canada to advance the biopharmaceutical industry.
We invested up to $173 million in Medicago in Quebec City and $4 million in Glycovax Pharma in Montreal. We invested in VIDO-InterVac in Saskatchewan, AbCellera Biologics in Vancouver, Variation Biotechnologies here in Ottawa, Precision Nanosystems, and ImmunoVaccine Technologies in Dartmouth, to name only a few.
We are here to invest in domestic production.